Laurence Venat

Limoges, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Journal: JCO precision oncology

Published: January 14, 2026

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.

Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial.

Journal: ESMO open

Published: November 11, 2025

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Journal: Translational oncology

Published: September 29, 2025

THERANOVA-LIM: Improving access to information on oral treatments for patients and pharmacists

THERANOVA-LIM: Improving access to information on oral treatments for patients and pharmacists

Journal: Bulletin du cancer

Published: August 22, 2025

Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.

Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.

Journal: Gynecologic oncology

Published: October 08, 2024

Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up.

Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up.

Journal: Breast (Edinburgh, Scotland)

Published: June 17, 2024

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research.

The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research.

Journal: Molecular cancer

Published: May 13, 2024

Administration of anti-HER2 and satisfaction of patients treated for breast cancer

Administration of anti-HER2 and satisfaction of patients treated for breast cancer

Journal: Bulletin du cancer

Published: August 30, 2023

Physician compliance with multidisciplinary tumor board recommendations for managing gynecological cancers.

Physician compliance with multidisciplinary tumor board recommendations for managing gynecological cancers.

Journal: Future oncology (London, England)

Published: May 26, 2023

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.

Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial.

Journal: Nature communications

Published: February 24, 2023

Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.

Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.

Journal: Frontiers in oncology

Published: November 21, 2022

Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.

Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 24, 2022

Showing 1-12 of 18

Last Updated: 09/26/2026